1. Home
  2. BGLC vs IMRN Comparison

BGLC vs IMRN Comparison

Compare BGLC & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

HOLD

Current Price

$3.86

Market Cap

10.1M

Sector

Health Care

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

HOLD

Current Price

$0.83

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
IMRN
Founded
2017
1994
Country
Malaysia
Australia
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
12.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BGLC
IMRN
Price
$3.86
$0.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.0K
105.9K
Earning Date
11-14-2025
02-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$9,465,006.00
$4,777,422.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
2.21
48.63
52 Week Low
$2.01
$0.68
52 Week High
$15.60
$2.48

Technical Indicators

Market Signals
Indicator
BGLC
IMRN
Relative Strength Index (RSI) 33.49 28.73
Support Level $3.89 $0.68
Resistance Level $4.14 $0.95
Average True Range (ATR) 0.14 0.05
MACD 0.00 0.01
Stochastic Oscillator 0.00 52.37

Price Performance

Historical Comparison
BGLC
IMRN

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: